Pitfalls Assessing the Role of Drug-Eluting Stents in Multivessel Coronary Disease

Annals of Thoracic Surgery

Volumn 85, Issue 1, 2008, Pages 25-27

  Desai, Nimesh D ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT;

CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DISEASE COURSE; DRUG ELUTING STENT; EDITORIAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REOPERATION; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 37249031392     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2007.08.063     Document Type: Editorial

References (19)

1. Yusuf S., Zucker D., Peduzzi P., et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 344 (1994) 563-570
2. BARI Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. N Engl J Med 335 (1996) 217-225
3. Serruys P.W., Unger F., Sousa J.E., et al. Randomized comparison of coronary artery bypass surgery and stenting for the treatment of multivessel disease. N Engl J Med 344 (2001) 1117-1124
4. Serruys P.W., Ong A.T., van Herwerden L.A., et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 46 (2005) 575-581
5. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 49 (2007) 1600-1606
6. SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. Lancet 360 (2002) 965-970
7. Pepper J.R. The stent or surgery trial longer-term follow-up (2006), World Congress of Cardiology, Barcelona, Spain Presentation 3466, September 4
8. Taggart D.P., and Thomas B. Ferguson lecture: coronary artery bypass grafting is still the best treatment for multivessel and left main disease, but patients need to know. Ann Thorac Surg 82 (2006) 1966-1975
9. Hannan E.L., Racz M.J., Walford G., et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 352 (2005) 2174-2183
10. Yang J.H., Gwon H.-C., Cho S.J., et al. Comparison of coronary artery bypass grafting with drug-eluting stent implantation for the treatment of multivessel coronary artery disease. Ann Thorac Surg 85 (2008) 65-70
11. Alderman E.L., Kip K.E., Whitlow P.L., et al. Bypass Angioplasty Revascularization Investigation. Native coronary disease progression exceeds failed revascularization as cause of angina after five years in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 44 (2004) 766-774
12. Bourassa M.G., Kip K.E., Jacobs A.K., et al., The Bypass Angioplasty Revascularization Investigation (BARI). Is a strategy of intended incomplete percutaneous transluminal coronary angioplasty revascularization acceptable in nondiabetic patients who are candidates for coronary artery bypass graft surgery?. J Am Coll Cardiol 33 (1999) 1627-1636
13. van den Brand M.J., Rensing B.J., Morel M.A., et al. The effect of completeness of revascularization on event-free survival at one year in the ARTS trial. J Am Coll Cardiol 39 (2002) 559-564
14. Hannan E.L., Racz M., Holmes D.R., et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation 113 (2006) 2406-2412
15. Kappetein A.P., Dawkins K.D., Mohr F.W., et al. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase. Eur J Cardiothorac Surg 29 (2006) 486-491
16. Stone G.W., Moses J.W., Ellis S.G., et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 356 (2007) 998-1008
17. Mauri L., Hsieh W.H., Massaro J.M., Ho K.K., D'Agostino R., and Cutlip D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 356 (2007) 1020-1029
18. Machecourt J., Danchin N., Lablanche J.M., et al., EVASTENT Investigators. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. J Am Coll Cardiol 50 (2007) 501-508
19. Win H.K., Caldera A.E., Maresh K., et al., EVENT Registry Investigators. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 297 (2007) 2001-2009